Transformative Raises $1.7M Seed Round After Developing Technology That Predicts Sudden Cardiac Arrest
July 27, 2020 07:00
Transformative, a healthcare startup whose software predicts sudden cardiac arrest, announced today that it has raised a $1.7 million seed round, led by Tera Ventures. The round includes funding from the Wellcome Trust, which provided Transformative a Healthcare Innovator Award, and from InHealth Ventures, which had previously invested in Transformative’s pre-seed round. Investors Andrus Oks of Tera Ventures and Nick Slater of AI Seed are joining Transformative’s board.
Transformative’s first patented technology predicts sudden cardiac arrest by analyzing data from patient monitoring devices that are standard in hospitals. Transformative will use its seed funding to obtain FDA clearance for its first product and to begin developing technologies that predict other life-threatening conditions, according to Josh Oppenheimer, MD, MBA, the company’s co-founder and CEO and a practicing emergency medicine physician.
“On each shift, I experience the tragedy of delayed care and the marvel of early, preventive interventions,” Oppenheimer said. “AI-augmented patient monitoring detects subtle changes preceding patient deterioration that are invisible to physicians, allowing us to be in the right place at the right time and save more lives.”
292,000 adults and 7,000 children suffer cardiac arrest in US hospitals each year, with only 25% surviving to hospital discharge, according to a 2019 estimate by the American Heart Association. Globally, 6 million people die from sudden cardiac arrest annually. The American Heart Association recommends early intervention – which Transformative’s technology enables – as the centerpiece of its guidelines on improving cardiac arrest care.
Jack Lewin, MD, the Chairman of the National Coalition on Health Care, the former CEO of the American College of Cardiology, and an advisor to Transformative, noted that many patients who survive in-hospital cardiac arrest suffer serious cognitive deficits due to delayed care. “While this is disheartening, there is new hope. Transformative has developed amazing and disruptive technology capable of predicting sudden cardiac arrest minutes to hours in advance, and with 94% accuracy. Transformative will soon help physicians and hospitals save many thousands of lives each year,” Lewin said.
Transformative’s other co-founders are Marek Sirendi, PhD, a physicist named to MIT’s Innovators Under 35 list, and Marek Rei, PhD, a machine learning researcher at Imperial College London. The company formed in 2016 through Entrepreneur First’s startup program and participated in the Philips HealthWorks program.
Oks, Tera Ventures’ founding partner, said that “investing in future technologies is essential so that the younger generation of researchers and innovators can develop solutions that will affect the future of all humankind.”
Transformative is a medical software company operating in the US, the UK, and Estonia. Its predictive patient monitoring software identifies patients at imminent risk of life-threatening medical events, enabling preventive care. Its first patented technology predicts in-hospital sudden cardiac arrest. For more information, go to www.transformative.ai.
About Tera Ventures
Tera Ventures is a venture capital firm based in Tallinn, Estonia and focused on exceptional founders from Estonia, Scandinavia and CEE disrupting digital space globally. Tera builds presence and networks in the markets where our portfolio companies want to expand to – the UK, the US, and Asia. With presence in Estonia, Finland, and California, Tera Ventures is supported by a global advisory network and provides portfolio companies with access to expertise and hands-on support necessary to grow from seed stage to successful exit. For more information, go to www.tera.vc.
Wellcome exists to improve health by helping great ideas to thrive. We support researchers, we take on big health challenges, we campaign for better science, and we help everyone get involved with science and health research. Wellcome is a politically and financially independent foundation.
About InHealth Ventures
InHealth Ventures (IHV) is a London-based early stage venture capital fund that invests across health IT and medtech at seed and series A. IHV’s mission is to contribute to bending the healthcare cost curve, improving patient outcomes, and enhancing the working lives of clinical and non-clinical staff. IHV is linked to InHealth Group, the largest private provider of preventative and diagnostic services in the UK and Ireland. Other recent investments include Clarify Health Solutions, Heydoc, Kheiron Medical Technologies, Laudio and Nye Health.
Head of Partnerships